MRC1 and neoplasm: Ex vivo, DCs were loaded with different tumor associated antigens (TAAs) using various strategies including (i) peptide or protein pulsing, (ii) loading with complete tumor lysate or (iii) tumor apoptotic bodies, and (iv) RNA transfection or (v) viral transduction [7]. In vivo, cancer antigens can be delivered to DCs by fusing them to monoclonal antibodies specifically targeting DC surface receptors such as mannose receptor, C type 1 (MRC1), CD209 (DC-SIGN), or DEC-205 [7–10].